What are the recommended dose modifications for apixaban in adults based on age, body weight, renal function, and hepatic impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Apixaban Dose Modification

For atrial fibrillation, reduce apixaban from 5 mg to 2.5 mg twice daily only when patients meet at least TWO of three criteria: age ≥80 years, body weight ≤60 kg, OR serum creatinine ≥1.5 mg/dL (133 μmol/L). 1

Standard Dosing by Indication

Atrial Fibrillation

  • Standard dose: 5 mg twice daily 2, 1
  • Reduced dose: 2.5 mg twice daily 2, 1

The dose reduction criteria are explicit and must be applied correctly to avoid both underdosing (which increases stroke risk) and overdosing (which increases bleeding risk). The 2024 ESC guidelines emphasize that reduced-dose DOAC therapy is not recommended unless patients meet DOAC-specific criteria, as inappropriate dose reduction leads to avoidable thromboembolic events 2.

VTE Treatment

  • Initial 7 days: 10 mg twice daily 1
  • After 7 days: 5 mg twice daily 1
  • Extended secondary prevention: 2.5 mg twice daily (after completing at least 6 months of treatment) 1

VTE Prophylaxis Post-Surgery

  • Dose: 2.5 mg twice daily starting 12-24 hours post-operatively 1
  • Hip replacement: 35 days duration
  • Knee replacement: 12 days duration

Dose Modification Based on Renal Function

Atrial Fibrillation Context

The FDA label and major guidelines provide clear guidance 3, 1:

  • CrCl >50 mL/min: Standard dosing (5 mg or 2.5 mg twice daily based on the two-of-three criteria)
  • CrCl 15-50 mL/min: Standard dosing applies (5 mg or 2.5 mg twice daily based on the two-of-three criteria)
  • CrCl <15 mL/min or dialysis: 5 mg or 2.5 mg twice daily based on the two-of-three criteria (though limited data exist) 3

Critical point: Serum creatinine ≥1.5 mg/dL is ONE criterion for dose reduction, but renal function alone does not mandate dose reduction unless combined with another criterion (age ≥80 or weight ≤60 kg). Recent real-world data show that dose-adjusted apixaban concentrations are significantly higher in patients with severe renal impairment, with approximately 3.3-fold higher levels in those with CrCl <30 mL/min 4.

Important Caveat on Renal Dosing

Unlike dabigatran (contraindicated in dialysis) or edoxaban (dose reduction at CrCl 15-50 mL/min), apixaban does not require automatic dose reduction based solely on renal function in the atrial fibrillation indication 3. The two-of-three criteria remain the standard.

Hepatic Impairment

The FDA label does not specify dose reductions for hepatic impairment in the standard prescribing information provided 1. However, recent pharmacokinetic modeling suggests:

  • Child-Pugh A: Approximately 96% of standard dose
  • Child-Pugh B: Approximately 81% of standard dose
  • Child-Pugh C: Approximately 58% of standard dose 5

In clinical practice, use caution with severe hepatic impairment, but no formal dose adjustment criteria exist in current guidelines.

Age Considerations

Age ≥80 years is ONE criterion for dose reduction, not an automatic trigger 2, 1. Patients aged 75-79 years receive standard dosing unless they meet two of the three reduction criteria. Pharmacokinetic studies show approximately 27% higher apixaban exposure in elderly patients, but clinical outcomes data demonstrate that appropriately dosed apixaban (whether standard or reduced) maintains efficacy and safety across age groups 6, 7.

Body Weight Considerations

Body weight ≤60 kg is ONE criterion for dose reduction 2, 1. Pharmacokinetic data show approximately 27% higher Cmax and 20% higher AUC in low body weight patients (≤50 kg), while high body weight patients (≥120 kg) have 31% lower Cmax and 23% lower AUC 6. However, body weight alone does not mandate dose adjustment—it must be combined with another criterion.

Common Pitfalls to Avoid

  1. Inappropriate dose reduction: Using only ONE criterion (e.g., age 82 alone, or CrCl 40 alone) to reduce dose leads to underdosing and increased stroke risk 2, 8

  2. Confusing serum creatinine with creatinine clearance: The criterion is serum creatinine ≥1.5 mg/dL, NOT creatinine clearance thresholds 1

  3. Over-reliance on renal function: Unlike other DOACs, apixaban's dose reduction is not primarily driven by CrCl cutoffs in atrial fibrillation 3

  4. Applying AF criteria to VTE: VTE treatment has NO dose reduction criteria based on age, weight, or renal function during the acute treatment phase 1

  5. Missing the "two-of-three" requirement: All three factors must be assessed, and at least TWO must be present for dose reduction 2, 1

Perioperative Management

  • High bleeding risk procedures: Stop 48 hours before surgery 1
  • Low bleeding risk procedures: Stop 24 hours before surgery 1
  • Resume: As soon as adequate hemostasis is established 1

The timing is based on CrCl >25 mL/min; for lower renal function, consider holding an additional 1-3 days 3.

Drug Interactions

While not explicitly detailed in the provided evidence, the 2024 ESC guidelines note that drug interactions exist with each DOAC and should be considered 2. Strong dual P-glycoprotein and CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may require dose reduction or avoidance.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.